4.7 Article

Protective role of kallistatin in renal fibrosis via modulation of Wnt/beta-catenin signaling

期刊

CLINICAL SCIENCE
卷 135, 期 3, 页码 429-446

出版社

PORTLAND PRESS LTD
DOI: 10.1042/CS20201161

关键词

-

资金

  1. Research Grants Council of Hong Kong [17151716, 17119818, C7018-16G]
  2. Health and Medical Research Fund (HMRF) of Hong Kong [05163596]
  3. Hong Kong Society of Nephrology/Hong Kong Kidney Foundation Research Grant 2017
  4. University of Hong Kong

向作者/读者索取更多资源

Kallistatin acts as a protective factor against renal fibrosis in chronic kidney disease by modulating Wnt/beta-catenin-mediated EMT and fibroblast activation. Its down-regulation in CKD progression suggests its potential as a valuable clinical biomarker and therapeutic target.
Kallistatin is a multiple functional serine protease inhibitor that protects against vascular injury, organ damage and tumor progression. Kallistatin treatment reduces inflammation and fibrosis in the progression of chronic kidney disease (CKD), but the molecular mechanisms underlying this protective process and whether kallistatin plays an endogenous role are incompletely understood. In the present study, we observed that renal kallistatin levels were significantly lower in patients with CKD. It was also positively correlated with estimated glomerular filtration rate (eGFR) and negatively correlated with serum creatinine level. Unilateral ureteral obstruction (UUO) in animals also led to down-regulation of kallistatin protein in the kidney, and depletion of endogenous kallistatin by antibody injection resulted in aggravated renal fibrosis, which was accompanied by enhanced Wnt/beta-catenin activation. Conversely, overexpression of kallistatin attenuated renal inflammation, interstitial fibroblast activation and tubular injury in UUO mice. The protective effect of kallistatin was due to the suppression of TGF-beta and beta-catenin signaling pathways and subsequent inhibition of epithelial-to-mesenchymal transition (EMT) in cultured tubular cells. In addition, kallistatin could inhibit TGF-beta-mediated fibroblast activation via modulation of Wnt4/beta-catenin signaling pathway. Therefore, endogenous kallistatin protects against renal fibrosis by modulating Wnt/beta-catenin-mediated EMT and fibroblast activation. Down-regulation of kallistatin in the progression of renal fibrosis underlies its potential as a valuable clinical biomarker and therapeutic target in CKD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据